FDA Warns Merck Over Marketing Efforts

The countdown to Brandweek is on! Join us, Sept. 12-16, to identify new growth opportunities, solve challenges and connect with power players. View the lineup and secure your pass.



WASHINGTON–Federal regulators warned Merck&Co. for improper marketing of its blockbuster arthritis drug Vioxx, saying the company had misrepresented the drug’s safety profile and minimized its potential risks, Tuesday’s Wall Street Journal reported.

The Food and Drug Administration, in a Sept. 17 warning letter, chided Merck (MRK) for its efforts to promote Vioxx to health professionals, which included audio conferences, a news release and statements made at medical conferences.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in